Fluidigm (FLDM) Tops Q4 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
February 10, 2020 4:05 PM ESTFourth quarter revenue of $32.4 million
Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates potential clinical value of using Imaging Mass Cytometry
Covance selects Fluidigm CyTOF technology to develop highly multiplexed human immune profiling services
SOUTH SAN FRANCISCO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) today announced financial results for the fourth quarter and full year ended December 31, 2019.
... More